Tag Archives: Gilead Sciences

Gilead Sciences (NASDAQ:GILD) Seeks Strenght in Blood Cancer Drugs; Spend $1.2 Billion in Previous Two Year

Posted on February 4, 2013 by Geoff Noir

Gilead Sciences, Inc (NASDAQ:GILD) has invested $1.2 billion in 2 years to acquire blood cancer medicines. The Foster City, California based Gilead Sciences is the world’s biggest producer of HIV drugs.

Leukemia treatment and other blood cancers is one of …

Posted in Healthcare, Main Post | Tagged BMY, Bristol-Myers Squibb, GILD, Gilead Sciences, GlaxoSmithKline, GSK, Merck, MRK, NASDAQ:GILD, NYSE:BMY, NYSE:GSK, NYSE:MRK | Comments Off

Merck (NYSE:MRK) Shatters Profit Guidance for Fiscal Year 2013; Fiscal Q4 Net Income Tumbles – MRK, GSK, NVS, BMY, GILD, JNJ, HLF, TEVA, CLSN

Posted on February 1, 2013 by Thomas Vedder

The Whitehouse Station, New Jersey-based Merck & Co, Inc’s (NYSE:MRK) current year profit forecasts tumbles as generic rivalry to its best selling medicine Singular will damage results.

The drug giant announced that earnings will be in the range of $3.60 …

Posted in Healthcare, Latest Headlines | Tagged BMY, Bristol-Myers Squibb, Celsion, CLSN, GILD, Gilead Sciences, GlaxoSmithKline, GSK, Herbalife, HLF, JNJ, Johnson & Johnson, Merck, MRK, NASDAQ:CLSN, NASDAQ:GILD, Novartis, NVS, NYSE:BMY, NYSE:GSK, NYSE:HLF, NYSE:JNJ, NYSE:MRK, NYSE:NVS, NYSE:TEVA, TEVA, Teva Pharmaceutical Industries | Comments Off

Biogen Idec (NASDAQ:BIIB) Post 2.7% Drop in Fiscal Q4 on Higher Outlays – BIIB, CELG, GILD, CLSN, KERX, PFE, BSX, BMY, HLF

Posted on January 28, 2013 by Geoff Noir

Biogen Idec Inc (NASDAQ:BIIB) reported fiscal Q4 earnings moved down 2.7% as the company’s attempts to increase its output pipeline masked its revenue expansion.

The biotechnology company also estimates fiscal year 2013 adjusted earnings in the range of $7.15 to …

Posted in Healthcare, Latest Headlines | Tagged BIIB, Biogen Idec, BMY, Boston Scientific, Bristol-Myers Squibb, BSX, CELG, Celgene, Celsion, CLSN, GILD, Gilead Sciences, Herbalife, HLF, KERX, Keryx Biopharmaceuticals, NASDAQ:BIIB, NASDAQ:CELG, NASDAQ:CLSN, NASDAQ:GILD, NASDAQ:KERX, NYSE:BMY, NYSE:BSX, NYSE:HLF, NYSE:PFE, PFE, Pfizer | Comments Off

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) Updates Claim of a Healthy Pipeline

Posted on January 14, 2013 by Thomas Vedder

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) lately gave an update on its pipeline. Isis Pharmaclaims of a healthy pipeline. The firm thinks 5 of its pipeline candidates can get acceptance within the coming five years. Isis Pharmaanticipates data (phase II or phase …

Posted in Latest Headlines, Services | Tagged arena, ARNA, BMY, Bristol-Myers Squibb, Elan, ELN, ENZ, Enzo Biochem, GILD, Gilead Sciences, ISIS, ISIS Pharmaceuticals, JNJ, Johnson, MYL, Mylan, NASDAQ:ARNA, NASDAQ:GILD, NASDAQ:ISIS, NASDAQ:MYL, NASDAQ:SQNM, NYSE:BMY, NYSE:ELN, NYSE:ENZ, NYSE:JNJ, Sequenom, SQNM | Comments Off

Healthcare Stocks In focus; Gilead (GILD) Board Approve 2-for-1 Stock Split while Peregrine Pharmaceuticals (PPHM) Posts Narrower Loss inQ2 – GILD, PPHM, PFE, INFI, OREX, JNJ

Posted on December 11, 2012 by Thomas Vedder

Investors reacted positively to the healthcare stocks on Monday. Key movement were seen in Infinity Pharmaceuticals Inc (NASDAQ:INFI) and Orexigen Therapeutics, Inc (NASDAQ:OREX) on percentage gainers side while Johnson & Johnson (NYSE:JNJ) was prominent stock on most active side.

Gilead …

Posted in Healthcare, Latest Headlines | Tagged GILD, Gilead Sciences, INFI, Infinity Pharmaceuticals, JNJ, Johnson, NASDAQ:GILD, NASDAQ:INFI, NASDAQ:OREX, NASDAQ:PPHM, NYSE:JNJ, NYSE:PFE, OREX, Orexigen Therapeutics, Peregrine Pharmaceuticals, PFE, Pfizer, PPHM | Comments Off

GlaxoSmithKline (NYSE:GSK) Plans to Buy Additional Stock in Indian Unit – GSK, MRK, NVS, SRPT, CTIC, SQNM, ESRX, STJ, GILD

Posted on November 26, 2012 by Thomas Vedder

GlaxoSmithKline PLC (NYSE:GSK)has shown interest in purchasing a further stake of almost 31.8% in its Indian division, GlaxoSmithKline Consumer Healthcare Ltd. , at 3,900 rupees ($70.3) a share, the UK-located firm stated in a report on Monday.

The proposal is …

Posted in Healthcare, Latest Headlines | Tagged Cell Therapeutics, CTIC, ESRX, Express Scripts, GILD, Gilead Sciences, GlaxoSmithKline, GSK, Jude Medical, Merck, MRK, NASDAQ:CTIC, NASDAQ:ESRX, NASDAQ:GILD, NASDAQ:SQNM, NASDAQ:SRPT, Novartis, NVS, NYSE:GSK, NYSE:MRK, NYSE:NVS, NYSE:STJ, Sarepta Therapeutics, Sequenom, SQNM, SRPT, STJ | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.